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Abstract
Background: The aim was to study changes in immunohistochemical expression markers of synovial and skin
inflammation, clinical outcomes and magnetic resonance imaging (MRI) scores with abatacept treatment in
patients with psoriatic arthritis (PsA).
Methods: Biological-treatment-naïve PsA patients with active disease including synovitis of a knee were
enrolled in this single-centre, crossover study. Patients were randomised to receive intravenous abatacept
3 mg/kg of body weight or placebo infusion on day 1, 15 and 29; thereafter abatacept 10 mg/kg of body
weight was administered every 28 days for 5 months. Clinical data were collected at each visit. Synovial
biopsy of the involved knee was obtained at baseline and 2 and 6 months. MRI of the same knee and skin biopsy
was performed prior to arthroscopy.
Results: Fifteen patients were recruited. Significant improvements in the joint-related measures were observed; 90%
were European League Against Rheumatism criteria responders and 30% achieved psoriasis area severity index (PASI)50
at 6 months. Reduction in synovitis (P = 0.016) and vascularity (P = 0.039) macroscopic scores consistent with decrease
in total MRI score (P = 0.016) were noticed. Abatacept decreased the immunohistological expression of FOXP3+ cells
(P = 0.027), specifically the expression of CD4+FOXP3+ regulatory T cells (Tregs) (P = 0.008) in the synovium
over 6 months. There was no significant clinical or immunohistological change in any of the skin measures.
Conclusion: This is the first study assessing synovial and psoriatic skin immunpathological changes following
abatacept treatment in PsA. Reduction in Treg expression in the synovium but not in the psoriatic lesion suggests
abnormal Treg function in PsA with differential suppressive capacity in the synovium compared to the lesional skin.
The results of this study demonstrate that abatacept 10 mg/kg of body weight might be an effective treatment option
for joint disease in patients with PsA.
Trial registration: Irish Health Products Regulatory Authority. Trial registration number: CT 900/489/1 – Abatacept
(case number: 2077284, EudraCT Number: 2009-017525-19, Protocol number: 77777). Registered on 12 March 2010.
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Background
Psoriatic arthritis (PsA) is a chronic immune-mediated in-
flammatory disease that affects peripheral joints, entheses
and axial sites along with skin and nails. In addition to the
characteristic extra-articular features, such as uveitis and
inflammatory bowel disease, PsA is also associated with
comorbidities [1, 2].
Interplay between the adaptive and innate immune sys-
tem, activation of T cells and subsequent production of in-
flammatory cytokines such as TNF, interferon (IFN)-γ, IL-
17 and IL-22 have a dominant pathogenic role in psoriatic
plaques [3, 4]. In PsA, CD8+ T cells may represent key
players that recognise antigens presented by human
leukocyte antigen (HLA) class 1 molecules [5]. CD8+ T
cells are found in greater numbers in synovial fluid and in
entheseal sites while CD4+ T cells are more abundant in
synovial tissue [5–7].
Regulatory T cells (Tregs) are a subset of CD4+
CD25high T lymphocytes that require forkhead box
transcription factor (FOXP3) for their suppressive func-
tion [4, 8, 9]. Tregs derived from the thymus mediate
suppression through a contact-dependent mechanism
including cytotoxic T-lymphocyte antigen 4 (CTLA-4)
[10]. Increased Treg expression compared to normal
skin has been reported in psoriatic lesions, irrespective
of the disease severity. Previous studies indicated an ab-
normal phenotype and impaired function of synovial
Tregs in rheumatoid arthritis (RA) and increased FOXP3
expression in synovial CD4+ T cells in rheumatoid factor
(RF)-negative RA and PsA compared to seropositive RA
[10–12]. Tregs isolated from peripheral blood and psori-
atic skin have dysfunctional activity in suppressing
effector T-cell responses in psoriasis [13–16].
Due to the heterogeneity of PsA, identifying appropri-
ate treatment for each individual can be challenging. Pa-
tients with peripheral arthritis that does not respond to
disease-modifying antirheumatic drugs (DMARDs) are
recommended for treatment with apremilast or biologic
agents (TNFi, IL-12/23i and IL17i), IL-12/23i and IL17i)
are recommended [17]. Since not all patients respond to
these agents and many patients’ initial responses wane
over time due to immunogenicity, poor tolerability and/
or adverse events, it has been important to develop new
therapies that target other key cytokines and immuno-
logic pathways [18]. Targeting T cells, the main media-
tors of the pathogenic processes in PsA, can potentially
have a significant role in the future immunotherapy of
the disease.
Abatacept is a soluble, fully human fusion protein con-
sisting of the extracellular domain of CLTA-4 linked to
human IgG1 [19]. Abatacept selectively binds to CD80/
86 on antigen-presenting cells blocking the costimula-
tory interaction with CD28 on T-cells, and thereby in-
hibits optimal T-cell activation and decreases production
of inflammatory cytokines such as TNFα, INFγ, IL-2 and
IL-6 [20–22]. Abatacept is approved in RA and juvenile
idiopathic arthritis [23, 24]. One phase 2 randomised
controlled trial of abatacept in PsA showed significant
American College of Rheumatologists (ACR)20 re-
sponses, but only modest improvement in skin measures
compared to placebo (PBO) [25]. More recently, a ran-
domised, placebo-controlled, phase 3 trial of abatacept
in PsA reported benefits of abatacept in ACR20 re-
sponses, regardless of TNFi exposure, with modest bene-
fit on psoriasis lesions [26].
A few studies have evaluated synovial changes after
different therapies in PsA [27], but the effect of abata-
cept on synovial and skin tissue has not been previously
studied. Therefore, our aim was to study changes in im-
munohistochemical markers of synovial and skin inflam-
mation, including FOXP3 expression, after introducing
abatacept treatment in PsA. Secondary objectives were
to (1) assess clinical outcomes and magnetic resonance
imaging (MRI) changes over time, (2) evaluate the im-
pact of a short period of abatacept 3 mg/kg of body
weight treatment compared to PBO and (3) investigate if
cell markers of synovial inflammation correlate with dis-
ease activity measures and MRI synovitis scores.
Methods
Patients
PsA patients fulfilling the classification criteria for
psoriatic arthritis (CASPAR) [28] with active disease of
≥3 months duration (tender joint count ≥3 and swollen
joint count ≥3), aged 18 to 80 years were recruited.
Patients had to have clinical synovitis of the knee and have
agreed to undergo synovial biopsies. Presence of a psori-
atic skin lesion was not requisite. Participants must not
have been exposed to a previous biologic DMARD.
Methotrexate (MTX) was the only concomitant synthetic
DMARD (sDMARD) permitted in the study. Patients who
were on a stable dose of MTX (7.5–25 mg/week) for
>3 months prior to randomisation remained on this stable
dose for the duration of the study. A decrease in the MTX
dosage was allowed in cases of toxicity. The use of a stable
dose of prednisolone <10 mg/day or its equivalent, and of
a nonsteroidal anti-inflammatory drug (NSAID) was per-
mitted during the study. Decrease in NSAIDs was permit-
ted but only if due to toxicity.
Key exclusion criteria were concurrent autoimmune
diseases or skin conditions other than plaque psoriasis,
arthritis mutilans, pregnancy, breast feeding, evidence of
latent or active tuberculosis, evidence of chronic or
clinically significant infection or malignancy.
Informed, written consent was obtained from all study
participants according to the Declaration of Helsinki.
The study was approved by St. Vincent’s Healthcare
Group Ethics and Medical Research Committee.
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Study design and treatment
This study was a single-centre, placebo-controlled,
crossover study of 15 patients with PsA. Patients were
randomised to receive abatacept 3 mg/kg of body weight
(approved dosing for RA) or PBO infusions on day 1, 15
and 29; thereafter abatacept 10 mg/kg of body weight
was administered every 28 days for 5 months (on day 57,
85, 113, 141 and 169). Treatments were administered as
a 30-minute intravenous infusion; dosing was calculated
based on body weight at screening (500 mg, 750 mg and
1000 mg for patients weighing <60 kg, 60–100 kg and
>100 kg, respectively).
Clinical and laboratory assessments
Demographic data collected included age, sex, psoriasis
and psoriatic arthritis disease duration, menopausal sta-
tus, previous use of sDMARDs, current use of MTX,
oral corticosteroids and calcium and vitamin D supple-
ments. Clinical assessments were performed at each
visit. Clinical variables included disease activity score in
28 joints (DAS28) with four variables (DAS28-erythro-
cyte sedimentation rate (ESR) and DAS28-C-reactive
protein (CRP)), tender joint count (TJC) 28 and 68,
swollen joint count (SJC) 28 and 66, number of digits
with dactylitis, enthesitis score based on the Leeds
enthesitis index (LEI), number of affected nails on the
hands (0–10) and psoriasis area severity index (PASI)
[29, 30]. Patients’ self-reported parameters such as dur-
ation of early morning stiffness (EMS), visual analogue
scale for global health (GVAS), pain and fatigue scores,
health assessment questionnaire (HAQ), dermatology
life quality index (DLQI) and PsA-specific quality of life
score (PsAQol) were recorded [30, 31]. Laboratory as-
sessments included a recording of the following parame-
ters: RF positivity, antibodies against cyclic citrullinated
peptides (aCCP), ESR and CRP.
Efficacy and safety assessments
Joint and skin-related response to abatacept or PBO was
assessed using the European League Against Rheuma-
tism (EULAR) response criteria and a 50% improvement
in the PASI score (PASI50) [32]. Safety evaluations were
obtained at each visit including routine laboratory tests
and monitoring of adverse events (AEs) for severity of
the event (mild, moderate, severe or very severe), the in-
vestigator’s opinion of its relationship to abatacept/PBO
treatment (not related, unlikely or possibly related) and
information on outcomes.
Synovial and skin biopsies
Arthroscopy of the same involved knee joint was per-
formed using a Wolf (Illinois, USA) 2.7-mm needle
arthroscope under local anaesthesia at three time points
(day 1, 57 and 169). Macroscopic synovitis and vascularity
were scored on a visual analogue scale (VAS) (0–
100 mm). Synovial membrane biopsies were obtained
from at least six sites within the joint (suprapatellar
pouch, medial and lateral gutters, infrapatellar and tibiofe-
moral regions and cartilage pannus junction near the pa-
tellar rim) using 1.5-mm grasping forceps [33, 34].
Under local anaesthesia, patients underwent a 6-mm-
punch skin biopsy at three time points (day -28, 54 and
166). Biopsies were taken from the centre of a target
psoriasis lesion from the same plaque [15].
Immunohistochemical analysis
Synovial and skin biopsies were embedded in Tissue-Tek
optimal cutting temperature (OCT) compound (Sakura,
Zoeterwoude, The Netherlands) and stored at -80 °C.
Cryostat sections (7 μm) were mounted on slides coated
with 3-aminopropyltriethoxysilane (Sigma-Aldrich St.
Louis, MO, USA), air-dried overnight, wrapped in foil
and stored at -80 °C. A routine three-stage immunoperox-
idase labelling technique was used [35]. Tissue sections
were thawed and acetone-fixed for 10 minutes. Immuno-
staining was performed on the Dako Autostainer 48 Link.
Sections were processed using the Dako Envision FLEX
Mouse Linker kit according to the manufacturer’s instruc-
tions. DAB was used as the chromogen and slides were
counterstained with hematoxylin. The synovial and skin
sections were incubated with mouse monoclonal anti-
bodies against T-cell-specific markers CD3 (1:25), CD4
(1:20), CD8 (1:50), CD31 (Dako Ready to use Antibody,
Clone numbers: CD3 – F7.2.38, CD4 – 4B12, CD8 – C8/
144B, CD31 – JC70A) (Dako, Glostrup, Denmark), and
FOXP3 (1:500) (Abcam, Cambridge, UK, Clone: 236A/
E7). Sections were also incubated with an appropriate
isotype-matched mouse monoclonal antibody (IgG1).
Negative control slides omitting the secondary antibodies
were also stained.
CD3, CD4 and CD8 expression in the biopsies were
scored using a well-established semi-quantitative scoring
method on a 5-point scale ranging from 0 to 4 (0 = no
staining, 1 ≤ 25%, 2 = 25–50%, 3 = 50–75%, 4 ≥ 75% stain-
ing). For evaluation of CD4+ cells, only cells with
lymphocyte morphology were included as CD4 can be
expressed by macrophages [36, 37]. CD31-expressing
microvessels were assessed under × 400 magnification by
counting the number of vessels staining per five high
power fields (HPF) on two levels when available (=10
HPF/slides). The result for one biopsy was extrapolated
from two HPFs, due to the size of the tissue sample.
Intranuclear staining for FOXP3 expression was assessed
in a semi-quantitative manner as a percentage over 300
cells. (More specifically, 300 lymphocytes were counted
at objective × 40 in “hot spots”, both in lymphoid aggre-
gates and lymphoid infiltrates, and the number of
FOXP3+ cells was divided by 3 to obtain a percentage;
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the result was then the average rounded up or down to
the nearest whole number.)
Immunofluorescence staining of synovial tissue
To examine synovial tissue co-localization of CD4 with
FOXP3, dual immunofluorescence staining was per-
formed on cryostat synovial sections. Cryostat sections
were defrosted at room temperature for 20 minutes and
fixed in acetone for 10 minutes. Slides were washed in
PBS for 5 minutes. Non-specific binding was blocked
using 1% casein in PBS for 20 minutes. Slides were co-
incubated with rabbit monoclonal antibody against CD4
(1:500, Abcam, Clone: EPR6855) and mouse monoclonal
anti-FOXP3 antibody (1:500, Abcam, Clone: 236A/E7).
IgG control antibodies were used as negative controls.
Following overnight incubation in a humidified chamber
at 4 °C, immunofluorescence sections were co-incubated
with Alexa 488 goat anti-mouse superclonal™ secondary
antibody (1:200, Invitrogen) and CyTM3-conjugated goat
anti-rabbit secondary antibody (1:500, Jackson Immu-
noResearch) for 60 minutes. Sections were mounted
with Antifade (Molecular Probes) and assessed by im-
munofluorescence microscopy (Olympus BX51). The
number of CD4+FOXP3+ Tregs at baseline and
6 months was scored manually by two independent
readers on cryostat sections by identifying cells that had
clear signals for co-expression of CD4 and FOXP3 on
merged images.
Magnetic resonance imaging
MRI scan of the same involved knee was performed in
each patient 3 days prior to arthroscopy at baseline, 2
and 6 months using a 1.5 T Signa Excite HD MRI scan-
ner (GE Healthcare, UK) and a dedicated eight-channel
array HD knee surface coil, with patients lying supine.
The examinations performed included intravenous con-
trast (Gadolinium diethylenetriamine penta-acetic acid)
enhanced, T1-weighted, fat-suppressed pulse sequences
in coronal, sagittal and axial planes. The following scan-
ning parameters were used: coronal, repetition time
(TR) 640 ms; echo time (TE) 16; slice thickness 4/1 mm;
field of view (FOV) 18; NEX 2; matrix 512 × 256; sagittal,
TR 500; TE 16; slice thickness 4/1 mm; FOV 22; NEX 2;
matrix 256 × 192 axial, TR 440; TE 11; slice thickness 3/
1.5 mm; FOV 16; NEX 3; matrix 224 × 192.
Images were scored using the psoriatic arthritis MRI
synovitis score (PsAMRIS) semi-quantitative method by
one consultant radiologist with a special interest in mus-
culoskeletal radiology, who was blind to patient identity
and scan chronology. Each knee was divided into four
anatomical regions ((medial (MED) and lateral (LAT)
parapatellar recesses, intercondylar notch (ICN) and
suprapatellar pouch (SPP)) and a synovitis score ranging
from 0 to 3 was assigned to each region (0 = normal
synovium, 1 = diffuse, even thickening, 2 = nodular thick-
ening, 3 = gross, nodular thickening) based on the overall
impression of the severity of synovial abnormality in the
three orthogonal scanning planes. A total MRI synovitis
score (MRIS) from the four regional scores ranging from
0 to 12 was calculated and used for analysis [38, 39].
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows version 20.0 (Armonk, NY, USA). Baseline charac-
teristics were described using mean (SD), median (IQR)
for continuous variables and percentage for counts. The
Wilcoxon test and the paired sample t test were used to
compare responses to abatacept treatment for clinical
measures, synovitis macroscopic scores and immunohis-
tological staining scores at 0 vs 2 months, 2 vs 6 months
and 0 vs 6 months. To measure the effect of the first
2 months of abatacept or PBO treatment over time on
cell markers of inflammation in the group we used a
general linear model (GLM) repeated measure (within-
subject factor: 0, 2 and 6-month time points, between-
subject factors: abatacept and PBO treatment groups,
and treatment duration). Correlation between synovial
cell markers, macroscopic scores, clinical parameters
and MRI scores were analysed using Pearson correlation.
P < 0.05 was considered as statistically significant.
Results
Demographic and disease-specific characteristics of the
patients
Fifteen patients (8 female and 7 male) with mean age of
45 (±14.6) years were recruited, and 14 subjects were
randomised. Seven patients received abatacept 3 mg/kg
of body weight and seven patients were given PBO infu-
sions on day 1, 15 and 29. Eleven patients received he
abatacept dose of 10 mg/kg of body weight from day 57.
In total 10 patients completed the study (Fig. 1). Out of
14 randomised subjects, 2 patients dropped out due to
commitment issues (1 patient in the 3 mg/kg of body
weight treatment arm and 1 in the PBO arm) and 2 pa-
tients were withdrawn because of an acute disease flare
(1 patient in the 10 mg/kg of body weight treatment
arm on day 71 and 1 in the PBO arm on day 40). Demo-
graphic and disease-specific characteristics of the group
are summarised in Table 1. All patients were of Cauca-
sian race. Mean disease duration was 18 years for psoria-
sis and 10 years for PsA. Four patients were on a stable
dose of MTX at the time of recruitment (one patient in
the 3 mg/kg of body weight treatment arm and three in
the PBO arm) and stayed on the same dose of MTX, the
remainder had not received any prior DMARDs; one pa-
tient (PBO arm) was on a stable dose of prednisolone
5 mg/day.
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Clinical responses of arthritis and psoriasis
All patients had active joint disease at baseline as
reflected by both physicians’ assessments and patients’
reported outcome measures (PROMs), such as morning
stiffness, pain, global health, fatigue, HAQ or PsAQoL
scores. Mean TJC68, SJC66, DAS28-ESR and DAS28-
CRP were 11.5 (±11), 6.9 (±7.4), 4.9 (±1) and 4.7 (±0.9),
respectively. Skin-related measures showed mild to mod-
erate psoriasis with mean PASI, DLQI and nail scores
4.5 (±4.6), 4.8 (±7.2) and 5 (±3.8), respectively (Table 1).
DAS28-ESR (P = 0.01) and DAS28-CRP (P = 0.042) im-
proved as early as 2 months. Significant improvements
in most of the joint-related measures and PROMs were
observed at 6 months compared to 2 months and to
baseline (data not shown). There was very little change
in skin-related outcomes. Change in PASI and DLQI
from 2 to 6 months was -5.4 (±11.7) and -4.2 (±11.1) in
the treatment, and -1.15 (±2.6) and 0.17 (±2.2) in the
PBO group, respectively.
According to the EULAR response criteria 73% and
90% of patients were EULAR responders after 2 and
6 months of treatment (46% and 80% good responders,
27% and 10% moderate responders, respectively).
PASI50 response at 2 and 6 months was seen in only 9%
and 30% of the patients.
Improvement of knee synovitis on MRI
MRI scans were available at 0, 2 and 6 months for 15, 11
and 10 patients, respectively. MRI synovitis scores im-
proved in each anatomical region of the knee through-
out the study. Mean total MRIS at baseline, 2 and
6 months were 8.1 (±3), 7.3 (±3.8) and 6.2 (±4.3), re-
spectively. There was a significant reduction in total
MRIS from 2 to 6 months (P = 0.047) and from 0 to
6 months (P = 0.016). MRIS at 6 months was associated
with change in DAS28-CRP from 2 to 6 months (rho
= -0.63, P = 0.049).
Macroscopic evaluation of the synovium
Synovial inflammation as assessed by arthroscopy
showed significant improvement throughout the study.
Mean macroscopic scores at baseline and 2 and 6 months
were 73 (±22.1), 41 (±29.7) and 44.4 (±34.3) for syno-
vitis, and 59 (±29.7), 46 (±27.6) and 34 (±29.6) for vas-
cularity, respectively. Significant reduction in synovitis
scores was noted from 0 to 2 months and from 0 to
6 months (P = 0.016), and in vascularity scores from 0 to
6 months (P = 0.039).
Immunohistological analyses of synovial and skin tissues
Synovial and skin biopsies were available at 0, 2 and
6 months for 14, 11 and 9 patients, and for 11, 9 and 7 pa-
tients, respectively. Mean scores of immunohistological
expression of CD3, CD4, CD8, FOXP3 and CD31 in the
synovium and in the skin prior to and following treatment
are summarised in Table 2. There was a trend toward re-
duction in CD8+ T cells, a reduction in CD4 expression
(P = 0.073) and a significant reduction in FOXP3 expres-
sion (P = 0.027) in the synovium following treatment at
6 months. Figure 2 shows representative, single-stained
images of decrease in CD4+ cells and in FOXP3+ cells
prior to and at 6 months after abatacept treatment.
FOXP3 expression was observed mostly in lymphoid folli-
cles; some peri-vascular staining was seen and some lining
layer staining was occasionally observed.
We did not find significant change in synovial CD3,
CD8 or CD31 expression during the study period. A
trend toward reduction in CD3+, CD4+ and CD8+ T
Fig. 1 Study design. Numbers of patients who underwent synovial and skin biopsies, and magnetic resonance imaging (MRI) in the abatacept
(ABA) and placebo (PBO) study arms at each time point. *One patient was not randomized (screening visit and first MRI only). **Four patients were
withdrawn from the study (two patients due to commitment issues (one in the 3 mg/kg of body weight treatment arm and one in the PBO arm)
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cells was also seen in the lesional skin in particular in
the first 2 months; however, significant change in ex-
pression was not observed for any of the cell markers
over the 6-month treatment period.
Dual immunofluorescence staining of synovial tissue
Recent studies have proposed that FOXP3 is not only
expressed by Tregs, but can be expressed by other types
of lymphoid or myeloid cells, and by some non-
haematopoietic cells such as epithelial cells [40]. To fur-
ther specify the phenotype of FOXP3+ cells we performed
dual immunofluorescence staining on synovial tissue sec-
tions with anti-CD4 and anti-FOXP3 antibodies.
Figure 3a-c shows representative images of immuno-
fluorescent staining in synovial tissue (nuclear staining of
FOXP3 (green), CD4+ T lymphocytes (red), and double-
stained CD4+FOXP3+ T lymphocytes (green nuclear
staining surrounded by red cytoplasmic staining). CD4 co-
localized with FOXP3 mostly in lymphoid follicles.
Figure 3d demonstrates quantification of double-stained
CD4+FOXP3+ cells in synovial tissue at baseline and 6-
months post treatment. Significant reduction (P = 0.008)
in the number of double stained CD4+FOXP3+ T-cells
was found in patients (n = 9) following 6 months abata-
cept treatment compared to baseline.
The impact of a short period of treatment with abatacept
3 mg/kg of body weight or placebo on clinical outcomes
and cell markers
Abatacept 3 mg/kg of body weight or PBO was given to 7
patients in each arm on day 1, 15 and 29. Clinical out-
comes, PROMs, and cell markers of synovial and skin in-
flammation were compared between the two treatment
arms at 0 and 2 months. Disease activity measures and cell
markers or their change over 2 months did not show sig-
nificant difference between the abatacept and PBO groups
(data not shown), with two exceptions: the MRIS was
higher at baseline (P = 0.02) and FOXP3 expression in the
skin was lower at 2 months (P = 0.028) in the treatment
group compared to the PBO arm. The GLM repeated
measure showed that the short PBO treatment did not
have a significant effect on the changes in expression of
cell markers of synovial and skin inflammation between
baseline and 2 and 6 months in the whole group.
Macroscopic evaluation of synovial inflammation
correlates with reduction in synovial cell markers
Both synovitis and vascularity scores correlated with
FOXP3 expression at 2 months (rho = 0.7, P = 0.024 and
rho = 0.65, P = 0.041, respectively), and improvement in
vascularity score correlated with reduction in FOXP3
expression from 2 to 6 months (rho = 0.64, P = 0.034).
Table 1 Patients’ demographic and clinical characteristics at
baseline
Variable Value
Demographic parameters
Age (years) 45 (±14.6)
Female/male, n (%) 8 (53)/7 (47)
Age onset of psoriasis (years) 23 (±15)
Psoriasis disease duration (years) 18 (±12)
Age onset of PsA (years) 35 (±15)
PsA disease duration (years) 10 (±9.6)
Previous sDMARDs, n (%) 3 (20)
Concomitant sDMARDs (methotrexate), n (%) 4 (27)
Currently taken corticosteroids, n (%) 1 (7)
Clinical parameters, physician’s assessment
aCCP+, n (%) 0
RF+, n (%) 1 (7)
ESR (mm/h) 27 (±11)
CRP (mg/L) 19 (±10.4)
DAS28-ESR 4.9 (±1)
DAS28-CRP 4.7 (±0.9)
TJC 68 11.5 (±11)
SJC 66 6.9 (±7.4)
Dactylitis (0–20) 1.1 (±1.8)
Enthesitis (0–6) 1.6 (±1.6)
Nail (0–10) 5 (±3.8)
PASI (0–72) 4.5 (±4.6)
Clinical parameters, patient-reported
Stiffness (minutes) 46 (±35.9)
Pain (0–10) 5.9 (±3.1)
GVAS (0 − 100) 56 (±28.6)
Fatigue (0–10) 5.9 (±2.8)
HAQ (0–3) 0.9 (±0.7)
DLQI (0–30) 4.8 (±7.2)
PsAQol (0–20) 8.6 (±5.7)
Results are presented as mean ± SD, median (IQR) or percentage. Dactylitis, the
number of affected digits. Enthesitis score is based on the Leeds enthesitis index.
Nail, the number of affected nails on the hands. Stiffness is early morning stiffness.
Pain scale ranges from 0 = no pain to 10 = pain as bad as it could be. The visual
analogue scale for global health (GVAS) ranges from 0 =worst imaginable health
state to 100 = best imaginable health state. The fatigue scale ranges from 0 = no
fatigue to 10 = fatigue as bad as it could be. The health assessment questionnaire
HAQ scale ranges from 0 = no difficulty to 3 = unable to perform activity.
PsA psoriatic arthritis, aCCP antibodies against cyclic citrullinated peptides,
RF rheumatoid factor, sDMARD synthetic disease-modifying antirheumatic
drug, aCCP antibodies against cyclic citrullinated peptides, RF rheumatiod
factor, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28-
ESR/CRP disease activity score based on a 28-joint assessment of pain or
swelling using the ESR/CRP-based formula (www.das-score.nl), TJC tender
joint count, SJC swollen joint count, PASI psoriasis area and severity index,
DLQI dermatology life quality index, PsAQol psoriatic arthritis-specific quality of
life score
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Table 2 Synovial and skin immunohistological expression of CD3, CD4, CD8, FOXP3 and CD31 prior to and following abatacept treatment
Baseline 2 Months 6 Months P value
0 vs 2 months 0 vs 6 months
ABA PBO ABA PBO ABA ABA PBO ABA
Synovium
CD3 2.66 (±1.2) 1.8 (±0.8) 2.3 (±1) 2.25 (±1.5) 2.22 (±1.3) 0.679 0.824 0.739
CD4 2.83 (±1.2) 2.4 (±1.5) 2.3 (±0.8) 2.75 (±1.3) 1.78 (±1.1) 0.296 1 0.073
CD8 1.66 (±0.8) 2 (±1) 1.3 (±1) 1.75 (±1) 1.33 (±0.7) 0.576 0.604 0.129
FOXP3 5 (±6) 4.4 (±4.4) 2.8 (±2.2) 4.6 (±4) 1.13 (±2.4) 0.407 0.807 0.027*
CD31 78.3 (±53.9) 85.6 (±50.2) 67.6 (±75.9) 155.5 (±136) 73.22 (±69.9) 0.621 0.482 0.813
Skin
CD3 2.6 (±0.8) 2.4 (±0.9) 2.25 (±1.5) 2.5 (±2.1) 2.43 (±1.1) 0.718 0.717 0.891
CD4 3.5 (±0.5) 2.8 (±1.1) 2.75 (±0.9) 4 (±0) 3.14 (±0.9) 0.182 1 0.891
CD8 2 (±0.6) 1.75 (±1) 1.5 (±0.6) 2 (±1.4) 1.71 (±0.8) 0.718 0.423 0.577
FOXP3 16 (±9.5) 9.2 (±10.7) 9.5 ±4.5 17.5 ±2.1 13.14 ±8.3 0.743 0.709 0.497
CD31 61.2 (±38) 65.4 (±20.5) 75.5 ±17.1 64.5 ±10.6 54.71 ±17.2 0.788 0.749 0.612
The Wilcoxon test and the paired sample t test were used for analysis. Results are presented as mean ± SD
Number of ABA samples at 0, 2 and 6 months: synovial n = 7, n = 6, n = 9; skin n = 6, n = 5, n = 7, respectively. Number of PBO samples at 0 and 2 months: synovial
n = 7, n = 5; skin n = 5, n = 4, respectively. Expression of CD3, CD4 and CD8 was scored on a 5-point scale (0–4). CD31 expression was scored by the number of
positive vessels/10 high power fields. Forkhead box protein transcription factor 3 (FOXP3) expression was scored as %/300 cells. ABA abatacept group, PBO
placebo group. *Statistically significant
Fig. 2 Immunohistological comparison of the expression of CD4+ and forkhead box protein transcription factor 3-positive (FOXP3+) T cells
(magnification × 10) in the synovial tissue prior to and at 6 months after abatacept treatment (patient #6). Baseline images show focal infiltration of
CD4+ T cells (a) and FOXP3+ T cells (b) in a villus. Decrease in CD4 expression and significant reduction in the number of FOXP3+ T cells are shown
(c and d, respectively)
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Safety
AEs were reported in a total of 12 patients (86%). Four
patients (57%) in the treatment arm receiving abatacept
3 mg/kg of body weight, 6 patients (86%) in the PBO
arm, and 8 patients (73%) who received the dose of
10 mg/kg of body weight from day 57 experienced mild
or moderate AEs. There were no cases of acute infusion
reaction. AEs possibly related to abatacept or PBO as
per the investigator’s opinion were reported in one
(headache, influenza-like symptoms) and two (diarrhea,
flare of psoriasis and arthritis) cases, respectively. There
were no serious adverse events.
Discussion
This single-centre, placebo-controlled, crossover study
demonstrates that abatacept reduced the immunohisto-
logical expression of CD4+ T cells and specifically
reduced FOXP3+ Treg expression in the synovium over
6 months. Abatacept 10 mg/kg treatment significantly
improved clinical measures including MRI synovitis
scores and arthritis-related PROMs in PsA with little
effect on skin-related outcomes.
Clinical efficacy of abatacept has been reported in pa-
tients with active RA, including those with an inad-
equate response to MTX or TNF inhibitors [41], in early
type 1 diabetes mellitus, and more recently, in primary
Sjögren’s syndrome [21, 42]. Whilst there was no major
clinical response to treatment with abatacept 10 mg/kg
of body weight in a phase-2 open-label 24-week trial in
ankylosing spondylitis [43], Mease et al. reported efficacy
of abatacept on joint symptoms in PsA and identified a
differential dosage effect of abatacept, with the dose of
10 mg/kg of body weight having more therapeutic effect
on arthritis than the 3 mg/kg regimen [25]. In line with
this study, we did not notice significant improvement in
joint-related outcomes with the dose of 3 mg/kg of body
weight, whereas the 10 mg/kg regimen led to significant
improvements in most joint-related measures at
6 months. Similarly, MRI synovitis scores improved sig-
nificantly over time only after administering the dose of
10 mg/kg of body weight. Abatacept has been shown to
have some clinical benefit in the treatment of psoriasis
[4]. In an open-label phase-1 study of abatacept in psor-
iasis, 50% or greater improvement of skin involvement
was achieved in patients using doses of 25 and 50 mg/kg
of body weight, and the same doses correlated best with
the reduction of epidermal hyperplasia and the decrease
in activated T cells in the skin [44, 45]. We observed
very little improvement in the PASI or DLQI over
6 months, but the treatment doses of 3 and 10 mg/kg of
body weight may have been too low to be of clinical
benefit.
Fig. 3 Representative images of immunofluorescent staining in cryostat synovial sections in a patient. a Nuclear staining of forkhead box protein
transcription factor 3 (FOXP3) (green), b CD4+ T lymphocytes (red), c double-stained CD4+FOXP3+ T lymphocytes (green nuclear staining surrounded
by red cytoplasmic staining), insert shows magnification × 40, white arrow points to a double-stained CD4+FOXP3+ T cell. d Reduction in the number
of double-stained CD4+FOXP3+ T cells from baseline to 6 months. Magnification of photomicrographs × 20
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Studies assessing synovial changes after initiating anti-
rheumatic therapy are limited in PsA. From these studies
it can be concluded that successful treatment leads to
deactivation of endothelium, reduced vascularity and re-
duction in infiltrating immune cells [27]. Immunpatho-
logical changes in the synovium following abatacept
treatment in PsA was evaluated in a single case report,
and suggested regression of synovial inflammation in a
patient refractory to TNF inhibitors [46]. We found sig-
nificant reduction in macroscopic scores for both syno-
vitis and vascularity after 6 months of abatacept therapy.
A trend toward reduction in CD8+ and CD4+ T cells
was observed throughout the study, but a statistically
significant effect of the treatment was only detected for
the reduction in the number of FOXP3+ Tregs in the
synovium.
Tregs play a central role in immune tolerance, sup-
pressing not only autoimmune responses but also aber-
rant or excessive immune responses to non-self-antigens
[4] Data on the presence of FOXP3+ Tregs in inflamed
synovial tissue are controversial. Enrichment of Tregs in
the inflamed joints was reported in a large cohort of pa-
tients with chronic inflammatory arthritis, including pa-
tients with PsA [47], whilst another study showed only
scarce synovial membrane expression of FOXP3+ T cells
during relapse in inflammatory arthritis [12]. Deficien-
cies in Treg function have been also identified in differ-
ent autoimmune diseases, including RA and psoriasis.
Anti-TNF therapy has been shown to induce a potent
population of Tregs in patients with RA; however, after
cessation of treatment the natural Treg defect persisted
[11, 13–15]. It has been suggested that reduced expres-
sion and functional abnormalities in Treg-associated
CTLA-4 could contribute to abnormal Treg function in
RA and may represent a target for therapy [11]. Data for
the effects of abatacept on Treg cell function are limited
and conflicting. Bonelli et al. showed that abatacept in-
creased the frequency of Treg cells in RA and inhibited
their suppressive capacity [48], whilst another study in
RA reported enhanced suppressive capacity of Tregs iso-
lated from peripheral blood [49]. Whether the reduction
in FOXP3 expression in the synovium we observed after
abatacept treatment is protective or pathogenic remains
unclear, since our study did not include detailed pheno-
typic or functional analyses of the Tregs. However, in
view of the significant improvement seen in arthritis
measures we speculate that the reduction in potentially
dysfunctional Tregs may be protective. In line with our
observations, a lack of retention of Tregs has been re-
ported after successful anti-inflammatory treatment with
intra-articular glucocorticoid injection, suggesting that a
specific treatment that modulates local FOXP3+ Treg
numbers and function would be of benefit for patients
with joint inflammation [12].
A study investigating the role of Tregs in the pathogen-
esis of psoriasis found increased Treg expression in lesional
skin compared to normal skin, in particular in the chronic
plaque type of psoriasis, irrespective of disease severity [15].
It has been proposed that the differential dosage effect of
abatacept in PsA that was reported in a previous study may
be due to the suppression of Tregs at higher doses [19, 25].
In this study, we did not observe a better skin response
with low-dose abatacept, possibly due to the small sample
size, although the study by Abrams et al. [45] suggests that
the abatacept doses used in our study may well have been
too low to achieve meaningful skin response.
In contrast to changes seen in the synovial tissue, we did
not demonstrate significant immunohistological change in
skin involvement in response to abatacept. Different
cytokine milieu in the joints compared to the skin may
account for this. A recent comparative genomic profiling
study of the synovium versus skin lesions in PsA revealed
clearly distinct gene expression patterns in the skin com-
pared to the synovium with a stronger IL-17 gene signa-
ture in the skin, and more equivalent TNF and IFN-γ
gene signatures in both tissues. The authors found fewer
Tregs in the synovium compared to the skin; however, the
difference was not significant [50].
Conclusions
In conclusion, this is the first study to assess both synovial
and psoriatic skin immunopathological changes following
abatacept treatment in PsA. The results of the study sug-
gest that treatment with abatacept 10 mg/kg of body
weight is associated with significant improvement in the
joint-related clinical outcomes but not skin-related out-
comes in biologic DMARD-naïve PsA patients and might
be an effective treatment option in patients with PsA. We
observed different patterns of efficacy of abatacept in the
joints and in lesional skin. Reduction in FOXP3+ T-cell
expression in the synovium but not in the psoriatic lesion
following abatacept treatment may indicate abnormal
Treg function in PsA with differential suppressive capacity
in the synovium compared to the skin. Comprehensive
studies are required on both the distribution and function
of Tregs, together with their complex interactions with
the local inflammatory milieu present in the psoriatic skin
lesion and inflamed synovium in PsA.
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